On Friday, Demant A/S (DEMANT:DC) (OTC: WILYY) received an upgrade from Jefferies, shifting from an Underperform to a Hold rating. The firm has set a price target for Demant at DKK275.00.
This adjustment comes despite a cut in the projected earnings per share (EPS) for 2024 by approximately 6%, acknowledging a subdued second quarter and an updated outlook for 2024.
The price target remains consistent due to a balance between a lower discounted cash flow (DCF) valuation and an increase in sector multiples, along with a reduced discount compared to peers as earnings are expected to reach a low point.
The rationale behind the upgrade to a Hold status is based on relative valuation, particularly noting that Demant’s stock has performed better than its hearing aid peers.
Competitors such as Sonova (SOON) have seen their stocks outperform, while Demant, alongside other firms like Amplifon (AMP (OTC:)) and GN Store Nord (GN), have experienced a decline of 15-20% over the past three months.
Despite the improved rating, Jefferies maintains a cautious perspective due to a lack of immediate catalysts that could drive the stock’s performance, as well as ongoing challenges in the Managed Care sector. These factors contribute to the firm’s decision not to adopt a more optimistic stance at this time.
Demant, a leading player in the hearing aid industry, is navigating through a period marked by both industry-wide challenges and company-specific dynamics. The updated assessment by Jefferies reflects a nuanced view of the company’s current position within the market.
In other recent news, Morgan Stanley upgraded the hearing aid company’s stock from an ‘Underweight’ to an ‘Overweight’ rating, also raising its price target from DKK268.00 to DKK320.00.
The decision was influenced by factors such as a significant drop in share price since March 2024, successful expansion in the Veterans Affairs (VA) channel, and the divergence in performance with competitor Sonova.
Morgan Stanley believes the market has already accounted for the risks following Demant’s previous earnings warning, suggesting the current earnings estimates are largely risk-free. They also see the current valuation of Demant’s shares as an attractive entry point, with the stock trading at what they consider trough levels compared to its peers.
However, Jefferies reduced Demant’s price target to DKK275.00, reflecting an 11% decrease from the prior target, due to a weaker-than-expected first-quarter performance. The firm also marked down the earnings per share forecast for 2024 by about 4%, primarily attributed to increased financial expenses.
Despite these challenges, Demant has maintained its financial guidance for the year. These are the recent developments regarding Demant’s financial performance and market position.
InvestingPro Insights
As Demant A/S (WILYY) adapts to market conditions, real-time data from InvestingPro provides a deeper perspective on its financial health and stock performance. With a market capitalization of $9.01 billion, Demant exhibits a P/E ratio of 25.44, which aligns with the company’s aggressive share buyback strategy, as noted by one of the InvestingPro Tips. Additionally, the company’s PEG ratio stands at 0.46, suggesting a favorable growth trajectory relative to its earnings. The data further reveals a robust gross profit margin of 74.61% over the last twelve months as of Q1 2023, underlining Demant’s efficiency in managing production costs relative to revenues.
InvestingPro Tips also highlight that Demant is trading at a low P/E ratio compared to its near-term earnings growth, indicating potential undervaluation. Moreover, analysts predict profitability for the company this year, a testament to its solid standing in the Healthcare Equipment & Supplies industry. For investors seeking more insights, InvestingPro offers additional tips for Demant, accessible through the dedicated link: https://www.investing.com/pro/WILYY.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
